Trizytek FDA Approval Status

FDA Approved: No
Brand name: Trizytek
Generic name: liprotamase
Company: Eli Lilly and Company
Treatment for: Pancreatic Exocrine Dysfunction

Trizytek (liprotamase) is a non-porcine derived enzyme replacement therapy in development for patients with pancreatic insufficiency. The FDA issued a complete response letter for liprotamase in April 2011.

Development timeline for Trizytek

Date	Article
Apr 18, 2011	Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
Jan 13, 2011	Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
Nov 17, 2008	Altus Pharmaceuticals Reaffirms Plan to Submit New Drug Applicationfor Trizytek Approval

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer